AKT1 and acute myeloid leukemia: Moreover, it should be noted that this study only focused on validating changes in AKT, the downstream molecule of mTOR; future studies are warranted to explore whether PARP3 also influences other mTOR downstream effectors, such as p70S6K, eIF4E, and PKCα, which may contribute to additional functional outcomes in AML pathogenesis.